Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity

Circulation

Volumn 136, Issue 21, 2017, Pages 2085-2087

  Escudier, Marion ^a,b,c   Cautela, Jennifer ^a,b,c   Malissen, Nausicaa ^a   Ancedy, Yann ^d   Orabona, Morgane ^a,b,c   Pinto, Johan ^a,b,c   Monestier, Sandrine ^a   Grob, Jean Jacques ^a   Scemama, Ugo ^a   Jacquier, Alexis ^a   Lalevee, Nathalie ^e   Barraud, Jeremie ^a,b   Peyrol, Michael ^a,b   Laine, Marc ^a,b   Bonello, Laurent ^a,b   Paganelli, Franck ^a,b   Cohen, Ariel ^d   Barlesi, Fabrice ^a   Ederhy, Stephane ^d   Thuny, Franck ^a,b,c  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Mediterranean Academic Association for Research and Studies in Cardiology   (France)

^c Groupe Méditerranéen de Cardio Oncologie gMEDICO   (France)

^d UNIVERSITÉ PARIS EST   (France)

^e Aix Marseille university   (France)

Author keywords

Cardiotoxicity; Immunotherapy; Neoplasms

Indexed keywords

ATEZOLIZUMAB; BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TROPONIN I; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; ATRIAL FIBRILLATION; CARDIOTOXICITY; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; CONGESTIVE HEART FAILURE; CONSULTATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DYSPNEA; ELECTROCARDIOGRAPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFORMED CONSENT; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LETTER; MALIGNANT NEOPLASM; MEDICAL RECORD REVIEW; MYOSITIS; ONCOLOGIST; PATIENT CARE; PATIENT REFERRAL; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TAKOTSUBO CARDIOMYOPATHY; TRANSTHORACIC ECHOCARDIOGRAPHY; VERY ELDERLY; CARDIOLOGY; CHEMICALLY INDUCED; CLINICAL TRIAL; FACTUAL DATABASE; FEMALE; HEART DISEASE; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALLERGY AND IMMUNOLOGY; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARDIOLOGY; CARDIOTOXICITY; DATABASES, FACTUAL; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 85042935565     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.030571     Document Type: Letter

References (5)

1. Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA Jr, Anders RA, Sosman JA, Moslehi JJ. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749-1755. Doi: 10.1056/NEJMoa1609214.
2. Wang DY, Okoye GD, Neilan TG, Johnson DB, Moslehi JJ. Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19:21. Doi: 10.1007/s11886-017-0835-0.
3. Semper H, Muehlberg F, Schulz-Menger J, Allewelt M, Grohé C. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1-negative squamous cell carcinoma of the lung. Lung Cancer. 2016;99:117-119. Doi: 10.1016/j.lungcan. 2016.06.025.
4. Behling J, Kaes J, Münzel T, Grabbe S, Loquai C. New-onset third-degree atrioventricular block because of autoimmuneinduced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma. Melanoma Res. 2017;27:155-158. Doi: 10.1097/CMR.0000000000000314.
5. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559-574. Doi: 10.1093/annonc/mdv623.